Mentions
Extended reach
Total likes
Video views
AI synopsis
The underlying tone reveals skepticism about the clinical value of evolocumab, with examples like mentions that despite a 60% LDL reduction, there was no significant decrease in cardiovascular mortality or all-cause death. The use of words like 'scam' and questions about cost-effectiveness emphasize the controversy and critical engagement surrounding its real-world impact.
Many discussions question the effectiveness of evolocumab in reducing mortality despite lowering LDL cholesterol, indicating mixed opinions or skepticism.
Discussions are somewhat focused on detailed trial results and costs, showing moderate curiosity about the clinical significance, but not widespread enthusiasm.
Posts reference specific studies (FOURIER, ODYSSEY) and critique aspects like cost and mortality benefits, reflecting a moderate level of detailed engagement.
Users highlight the disconnect between LDL reduction and actual mortality benefits, suggesting the research impacts debates on treatment value rather than immediate clinical changes.
(6/6) Zrodła: ORYGINALNE BADANIE: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease ( https://t.co/jXM5AdEMk0 ) RENAALIZA: Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a
FOURIER
15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even better”. The best proof of this is the FOURIER trial (
@KenDBerryMD Actual study. https://t.co/TOuTRYXOwd 15% reduction in the risk of cardiovascular death, myocardial infarction, stroke, and a 20% reduction in the risk of the more clinically serious key secondary end point of cardiovascular death, myocardial infarction, or stroke.
https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely promoted medicine available for lowering LDL cholesterol to levels as low as 30 mg% does not show the slightest improvement in all-cause death, cardiovascular https://t.co/0WkQmLN043
13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin therapy:
Dr Paul Saladinos discusses the potential health effects of plant chemicals called phytoalexins and their medicinal properties, questioning traditional views on plant consumption and emphasizing the importance of…
Evolocumab, a PCSK9 inhibitor, was studied to see if it reduces the risk of major cardiovascular events in patients without prior heart attack or stroke but with atherosclerosis or diabetes and elevated LDL cholesterol…
Does low cholesterol harm the brain? This video explores the effects of statins and other cholesterol-lowering drugs on dementia risk, alongside insights from a study on alirocumab's benefits for cardiovascular outcomes…
This video discusses the 2018 guideline developed by major health organizations, providing evidence-based recommendations for assessing, preventing, and managing high blood cholesterol to reduce cardiovascular risk. It…
Dr Nadir Ali, an experienced interventional cardiologist, discusses the impact of lifestyle changes, dietary fats, and LDL cholesterol on heart health, alongside insights from recent clinical trials like evolocumab's…
This video reviews the basics of high cholesterol and lipid panels, discussing lipid targets and management strategies. It also explores the influence of statin therapy on cognitive decline and dementia, emphasizing the…
This video discusses recent research on left atrial appendage closure as a safe and effective alternative to anticoagulation in high-risk atrial fibrillation patients. It highlights reduced bleeding complications and…
This video discusses the safety and efficacy of lowering LDL cholesterol levels to very low levels, based on the FOURIER-OLE trial. It highlights how evolocumab, a monoclonal antibody, significantly reduces…
An update in trial interpretation CI and Pvalues percutaneous tricuspid interventions and news on HDL and humility in Medicine are the topics John Mandrola MD covers in this weeks podcast. This podcast is intended for…
This week, we delve into the critical findings regarding cardiac troponin I levels. A recent study reveals a significant correlation between elevated troponin levels post-surgery and increased 30-day mortality…
This video discusses causes of sudden death, inclisiran, and cardiovascular outcomes associated with alirocumab for patients recovering from acute coronary syndrome. Learn how these treatments can significantly reduce…
The safety of very low LDLC, sacubitril-valsartan's promise in heart failure, and the impact of SGLT2 inhibitors are discussed in this podcast. It analyzes recent findings on treatment outcomes, including…
RT @deepakdeepak: https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely pro…
RT @deepakdeepak: https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely pro…
RT @deepakdeepak: https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely pro…
RT @deepakdeepak: https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely pro…
RT @deepakdeepak: https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely pro…
RT @deepakdeepak: https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely pro…
https://t.co/mGN50Zh72X https://t.co/wA7SfGhrac The general public may be shocked or bemused to learn that a widely promoted medicine available for lowering LDL cholesterol to levels as low as 30 mg% does not show the slightest improvement in all-cause death, cardiovascular https://t.co/0WkQmLN043
RT @UniversOfMemory: (6/6) Zrodła: ORYGINALNE BADANIE: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease ( https://…
RT @UniversOfMemory: (6/6) Zrodła: ORYGINALNE BADANIE: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease ( https://…
(6/6) Zrodła: ORYGINALNE BADANIE: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease ( https://t.co/jXM5AdEMk0 ) RENAALIZA: Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a
RT @cardiomet_CE: 9b) FOURIER showed that the monoclonal antibody #PCSK9 inhibitor #evolocumab significantly reduced ischemic events in pat…
9b) FOURIER showed that the monoclonal antibody #PCSK9 inhibitor #evolocumab significantly reduced ischemic events in patients with stable #atherosclerosis. See
@BigDDaddyCali @MasalaFry69 @squirrelpalooza @Rizabellepow @ErinGoBragh360 Incorrect. Here is a Mendelain randomization study regarding genetic LDL irrelevant to diet- though accounted for in p value calculations: https://t.co/jIXEiQNWgV And of course the medication trials and studies with mechanisms solely on LDL reduction: https://t.co/XQVaTEa8I9
@drjasonfung @drjasonfung It is very easy to prove that the statins work, at least for a big part through other mechanism than LDL lowering. Take the repatha study https://t.co/MUjPyv2kOQ It reduces the LDL by 60%. (1.45mmol/l) But has no effect on cardiovascular mortality and on MACE only
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
@euglycemic @thelowcarb_rd Both FOURIER (stable CAD, high risk) and ODYSSEY OUTCOMES (ACS) lowered MACE
@jibtie @NutritionMadeS3 There's no direct comparison, admittedly. In the FOURIER Trial, Evolocumab had massive LDLc reductions & reduced CV events but had no mortality benefit after 2 years. Yet in the 2 year Jupiter trial, a statin reduced mortality with tiny LDLc reductions https://t.co/lMUpBMBWUs
@robertlufkinmd @robertlufkinmd you have to add the PSK9 inhibitors, which are very effective in reducing LDL, but worse than statins to reduce the cardiovascular endpoints. https://t.co/MUjPyv2kOQ An incredible 60% reduction in LDL, lead to no effect on cardiovascular mortality and only 27% for https://t.co/gwUDJ52fGH
@SandmanRT @davykevinp @ArrienV @drscottyk This is the study protocol. If you're interested in the power calculations, termination criteria, etc., the first place to look would be here https://t.co/VV11PVU3cB
@CircAHA @Bweber04 @AbbateAntonio The FOURIER study shows no effect on cardiovascular death HR 1.05 https://t.co/MUjPyv2kOQ, whereas the COLCOT study shows a reduction of 16% HR 0.74. https://t.co/K7H5ZrBZuY Price for Evolocumab 561$ a month. Price for 1 month colchicine 15$ Guess, which is heavily promoted in
OPINION: FROM PROVE IT, TO IMPROVE IT , TO FOURIER, A NICE SUMMARY OF LIPID LOWERING LITERATURE. I THINK YOU SHOULD KNOW THIS! https://t.co/lexSOMQqUA https://t.co/3TOOphplym https://t.co/fJdeCi71BG https://t.co/ASjcqbCWFr
@ColDaveCrockett @PeterAttiaMD @Amgen psk9 inhibitors are particular ineffective to avoid CV morbidity and mortality. https://t.co/MUjPyv2SEo No effect whatsoever on CV mortality and only a marginal effect of 15% on morbidity. PSk9 inhibitors are a real scam. Use olive oil ad libitum and reduce your CV mortality by https://t.co/gm2clI8RKF
https://t.co/OuwFClRDA8 https://t.co/KxTU8fEaom 最大最長PCSK-9阻害剤試験FOURIER CVDでstatin27,000人≦ 主要血管event有意⬇️evolocumab9.8% vs. placebo11.3% 2.2年後中止 CVD
@LDLSkeptic Cholesterol Treatment Trialists’ Collaboration had around 175,000 participants and median follow-up around 5 years (https://t.co/wQkjOyFrbl); FOURIER had 27,564 participants and median follow-up of 2.2 years (https://t.co/E6fv35cj4H).
@DanClintonRN Huh, FOURIER is a positive trial https://t.co/Bi9uRVoSyy
RT @sigal_alan: Links para mas info: https://t.co/9Ani2CwOHe https://t.co/VW3LeD30zo https://t.co/BN70Bnt2jK https://t.co/1cknwROFf8 ht…
Links para mas info: https://t.co/9Ani2CwOHe https://t.co/VW3LeD30zo https://t.co/BN70Bnt2jK https://t.co/1cknwROFf8 https://t.co/8oDAFUQ4Zh
FOURIER
@Ikat0 @im_dori2 @Drlipid @jpapi7 https://t.co/nY7u8f5J3r NNT of like 200 to prevent 1 CV death. https://t.co/7PsE6feVcO No CV death improvement, NNT 100 to prevent an MI. Total mortality benefit likely noise given lack of CV death benefit (eg would mean it reduces infection or CA death better than CV).
@KenDBerryMD Actual study. https://t.co/TOuTRYXOwd 15% reduction in the risk of cardiovascular death, myocardial infarction, stroke, and a 20% reduction in the risk of the more clinically serious key secondary end point of cardiovascular death, myocardial infarction, or stroke.
一方でレパーサと違い現時点では心血管イベントに対する直接のエビデンスはなく急いで切り替えるらものではなさそうです。 薬価的には単純計算でレパーサの1.5倍と高額ですが半年に一回なので高額療養費制度を使えば人によってはお得かもしれません。 https://t.co/bbgkfXgFev
@JeffA47854828 @drpablocorral @Drlipid @MattBMartin @NEJM @JohnKastelein @society_eas @BNordestgaard @ProfKausikRay @LaleTokgozoglu @DrMarthaGulati @ErinMichos @rauldsf_santos @KarleziAlonso @Lpa_Doc https://t.co/NFsGAhmnQ2 https://t.co/XZOJKLUFAh https://t.co/01hDvJxldo https://t.co/SS9uD60C1Y
@DanClintonRN @holmanm This is the study the PSCK9 inhibitor "drug pushers" use to confuse unwitting patients to believe RRR over the more important ARR Ref #2 in image below: https://t.co/AYxs0eXs04 In your table, "Death from any cause" - More people died (444) USING this poison vs the placebo (426) https://t.co/PpycIF1MDN
@BioLayne @BioLayne It had nothing to do with outliers, it's more fundamental. All studies where drugs are used to reduce LDL, and they have no other property, show an extremely low effect on CV events. PSK9 Inhibitor = -15% https://t.co/INDcnnj3Ss Ezetemib = No effect in familial
@holmanm Beleive this is the link to the actual study, with Table 2 capturing the endpoints labeled in @holmanm's image above: - CV death: 251 (#bigpharma) vs 240 - Death, any cause: 444 vs 426 Where's the measurable benefit of lowering your cholestrol? https://t.co/Yval6hnAYF https://t.co/rXGL8CpfWj
@neeche41 @DanClintonRN @DavidLBrownMD @DrMarthaGulati You mean this one? https://t.co/rGoCWaMk3B
11/ Addition of #PCSK9 inhibitors to optimised #statin therapy further reduces #CV risk, but residual risk remains.
@bucksfan510 @holmanm The number of cardiovascular deaths is also higher in the evolocumab group: 251 deaths vs 240 in controls See table 2 in https://t.co/Uc0b0Hm6HD
@Tellit007 @Clint_OMeley @NutritionMadeS3 @NegDiscountRt @Drlipid https://t.co/7YYcSaA9So
@drimamofficial @MohammedAlo @shiv_twitts https://t.co/QjKLk6fuGz
@MohammedAlo @shiv_twitts https://t.co/6VleOS3hiE
#脂質異常症 PCSK9阻害薬 こっちの方がまだエゼチミブよりはエビデンスありそうやね。使わんけど(笑) 高強度スタチンを7割くらいの人が使ってLDL90くらいの群にPCSK9使ってみたって論文 死亡は減らないけど心筋梗塞は減らせるみたい まぁ高いから使わんけど(繰り返し) https://t.co/LRVOX4bP3J
@DrNaveedPirzad1 That data is already there- Fourier https://t.co/CvnflA8kR6
RT @raphaels7: fun debate w/ @DoctorTro yesterday! all-cause mortality in statins: HPSCG 2005 https://t.co/nmL25pLZFy, 4S trial 1994 https…
@ExMuslimsMN I mean here's just one example: https://t.co/NnqdGNLxHI
@JesperLundbom That's not true at all. You can read the study yourself. It's free. https://t.co/qzBHSsZjc6
@DanClintonRN @Paddy_Barrett A meta analysis is a collection of RCTs? I’m not sure what other evidence would be convincing. Here’s one of the specific trials. All I was saying was that PCSK9i do have CVOT data. https://t.co/y7HlatxDAR
The FOURIER trial : https://t.co/LEAg3irDC1
@ophirnahum99 תודה אופיר! אני לא יודע לגבי חברות מסחריות, אבל בעשורים האחרונים פורסמו המון עבודות שהראו שככל שהורידו את רמות ה-LDL יותר, כך הסיכון להתקפי לב ולשבץ פחת. יש כל כך הרבה עבודות כאלה, ככה שזה מאוד משכנע הנה למשל 2 עבודות נבחרות: https://t.co/BI3l1tTnQW https://t.co/uIzau3B5x6
@Drlipid @society_eas @fhpatienteurope @TheFHFoundation Maybe because a 60% reduction in LDL had no impact on mortality in the first study. 10.1056/NEJMoa1615664 How do you explain this?
@Umair2017 severe renal dysfunction excluded https://t.co/O5JjMxH35f
@AhmetFU38380786 @dr_rich @mgtmccartney 1. Only *non*-fatal MIs (& revasc'n) & strokes had statistically sig ⬇️ (L pic) 2. Authors state 2° benefits 'exploratory' (sic) 3. With an NNT of ≥65, & a cost just shy of $1bn per event prevented, its cost benefit is *at best* debatable (R pic) [ref: https://t.co/jpthvdIwUy] https://t.co/PqbG24bTXV
スタチンにエボクロマブを上乗せすると、心血管複合アウトカムの改善がみられた。 https://t.co/sZcdXQ6EWE
@pjungar @CarnalDancer @MarkBski @holmanm https://t.co/NnqdGNLxHI
@IAm48189155 @TheCarnivoreLaw @jeff_sweaney @MarkBski https://t.co/NnqdGNLxHI
27b)
@hoffsbeefs @VishalGulati_ i think for the PCSK9 inhibiting antibodies there was a one-year trial which was enough to generate a claim about reduced events (heart attack, stroke). thought the trial had ~30,000 people in it https://t.co/tYF6ZbsjOX
RT @cardiomet_CE: 15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even b…
RT @cardiomet_CE: 15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even b…
RT @cardiomet_CE: 15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even b…
RT @cardiomet_CE: 15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even b…
RT @cardiomet_CE: 15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even b…
15) Indeed, with respect to reducing subsequent events in patients with known CAD, the rule is that “even lower is even better”. The best proof of this is the FOURIER trial (
RT @cardiomet_CE: 29) The ODYSSEY OUTCOMES (
29) The ODYSSEY OUTCOMES (
RT @cardiomet_CE: 13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin…
RT @cardiomet_CE: 13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin…
13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin therapy:
fun debate w/ @DoctorTro yesterday! all-cause mortality in statins: HPSCG 2005 https://t.co/nmL25pLZFy, 4S trial 1994 https://t.co/J0EYwvWxGa, Kristensen 2015 https://t.co/KP5HqbmIdp And PCSK9i: FOURIER 2017 https://t.co/9hvNxT5SfS, Schwartz 2018 https://t.co/psJvTKidxz https://t.co/Wyjy2dsY4S https://t.co/uBwH9RGg3u
@dbechek1 @Lpa_Doc @Drlipid @ionispharma 1. https://t.co/Io1MD7CU6O 2. https://t.co/M5wDrKuzm8
https://t.co/bkiqHyT934 https://t.co/o6LOVbFaTr
https://t.co/z02C3JA7Dq) - Metanalisis del 2016 (https://t.co/9HZVfDIQH5) - Metanalisis del 2018 (https://t.co/RrcHomEIYh)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM https://t.co/IrM7wkmcHT
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM https://t.co/pbF3Q0ZhHH
@jlane_boston @AvinunReut Actually PCSK9 is the BEST example. Loss of function variants in PCSK9 results in 40% reduction in LDL (https://t.co/wEIHI2qZiB). And blocking PCSK9 using monoclonal antibody results in 59% reduction in LDL (https://t.co/azGLinct1a)
Dr. Nadir Ali's health optimizaton advice. He is an interventional #cardiologist with over 25 years of experience. He is also the chairman of the Department of Cardiology at Clear Lake Regional Medical Center. @eatmostlyfatali @CarnivoreMD https://t.co/o6Fkonx83F
LDL >70 ng/dL con máxima tolerancia a esta estatinas, considerar ezetimiba. Si LDL >70 con D.max estatina y ezetimiba, justifica inhibidor de PCSK-9 (Evolocumab) eficaz en px c/s DM y disminución riesgo relativo del 27% de muerte cardiovascular, IAM. DOI: 10.1056 / NEJMoa1615664 https://t.co/g8acZx8cEx
@raphaels7 @LDLSkeptic @ethanjweiss @DrAseemMalhotra referring to FOURIER trial Sabatine (2017)? https://t.co/WxArjQl39f
3/5: it only took #FOURIER 27,654 pts to find a 15% ⬇️ in 5p MACE, with profound ⬇️ LDL (59%), similar to ODYSSEY OUTCOME (15%, 55%). Seems like a disconnect b/t LDL and MACE https://t.co/DhL16vzsva
@jillbrownfitnes it's really a Q for specialists @Drlipid @drjkahn @DBelardoMD @KoushikReddyMD as far as stroke, evolocumab seems to lower risk of ischemic without raising hemorrhagic https://t.co/4EyPpuzgWD but if any of the ppl above disagree with me, go with them! :)
@KoushikReddyMD hm and FOURIER also showed lower HR for ischemic, no change for hemorrhagic... interesting https://t.co/4EyPpuhFy3
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. https://t.co/hsaGEcTGMj
RT @SVNefro: @EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejer…
RT @SVNefro: @EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejer…
RT @SVNefro: @EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejer…
@EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejerap @almucastro01 @sinaptopodina Fourier evolocumab https://t.co/LeBLpOEJYd Odyssey alirocumab https://t.co/FINFGozwVb
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
Pero no me crea a mí: si quiere ver las declaraciones de conflictos de intereses de cada uno de los 12 autores, puede entrar a: https://t.co/A3NuVtsRph y va a: Contents -> Supplementary Material -> Disclosure Forms Allí están las declaraciones de CdI de todos los autores.
Evolocumab y Resultados Clínicos en pacientes con enfermedad cardiovasular (Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease) NEJM - mayo, 2017. https://t.co/A3NuVtsRph
PCSK9 inhibitor in combination with a statin demonstrated a 59% reduction in LDL cholesterol compared to placebo and a 15% risk reduction of cardiovascular events (Sabatine at al (2017) https://t.co/YOO7Ebp3sj
RT @puddleg: Try to remember that this was a trial in which treatment did not reduce cardiovascular death (1.05) or all-cause mortality (1.…
RT @puddleg: Try to remember that this was a trial in which treatment did not reduce cardiovascular death (1.05) or all-cause mortality (1.…
RT @puddleg: Try to remember that this was a trial in which treatment did not reduce cardiovascular death (1.05) or all-cause mortality (1.…
@JAMACardio @TIMIStudyGroup @BrighamWomens Try to remember, because you won't read it here, that this was a trial in which treatment did not reduce cardiovascular death (1.05) or all-cause mortality (1.04), despite these benefits. https://t.co/KOA33aFyxL
Try to remember that this was a trial in which treatment did not reduce cardiovascular death (1.05) or all-cause mortality (1.04), despite these benefits. https://t.co/KOA33aFyxL https://t.co/WAY31CncH2
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM https://t.co/9dQykTKlG7 こっちのＡＥにも味覚変化は報告ないな
Sabatine, M. S.-Evolocumab and clinical outcomes in patients with cardiovascular disease https://t.co/QLIgiCA17v
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @VernersViews: Facts about Repatha, one of the latest cholesterol-lowering drugs. Cost: $14,000 per year NNT: 66 All-cause mortality: no…
RT @medevidenceblog: The question is whether a 1.5% ARR in a composite endpoint w #PCSK9 is worth $15,000 (or even 1/3 that) per year. Evol…
The question is whether a 1.5% ARR in a composite endpoint w #PCSK9 is worth $15,000 (or even 1/3 that) per year. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM https://t.co/Pxsqa5iD1i
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. - PubMed - NCBI https://t.co/hsaGEcTGMj
Evolocumab associated with significantly below target reduction in LDL-C and 15% + reduction in cardiovascular events - how much lower do we need to go with LDL-C ? https://t.co/RcpsnRfJpf #diabetes #badcholesterol
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. - PubMed - NCBI https://t.co/rPerzhJ46p
BC
DD
DK
A
K
VG
FJ
T
PZ
PŻ